ABT-126 clinical trials
Also written ABT-126.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ABT-126 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABT-126
- 14
Studies by the year they started
14 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
AbbVie (prior sponsor, Abbott) (8) · Abbott (5) · AbbVie (1)
Studies
Open first, then newest update. How each study uses ABT-126 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2AbbVie (prior sponsor, Abbott)NCT01676935Written as ABT-126How we know
- Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2AbbVie (prior sponsor, Abbott)NCT01690195Written as ABT-126How we know
- A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01655680Written as ABT-126How we know
- A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01678755Written as ABT-126How we know
- Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01095562Written as ABT-126How we know
- Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)TerminatedPhase 2AbbVieNCT01834638Written as ABT-126How we know
- Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01527916Written as ABT-126How we know
- Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01549834Written as ABT-126How we know
- Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00948909Written as ABT-126How we know
- A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's DiseaseCompletedPhase 1AbbottNCT01482845Written as ABT-126How we know
- Pharmacokinetic Study of ABT-126 in Healthy VolunteersCompletedPhase 1AbbottNCT00959634Written as ABT-126How we know
- Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy VolunteersCompletedPhase 1AbbottNCT00912431Written as ABT-126How we know
- Pharmacokinetic Study of ABT-126 in Stable Subjects With SchizophreniaCompletedPhase 1AbbottNCT01043458Written as ABT-126How we know
- A Safety and Tolerability Study of ABT-126 in ElderlyCompletedPhase 1AbbottNCT00867399Written as ABT-126How we know